Inflammation resolution is regulated by specialized pro-resolving lipid mediators (SPMs) and the levels of SPMs are found decreased in Alzheimer’s disease (AD) brain. We have previously found that one of the SPMs, Maresin1 (MaR1), improved neuronal survival and increase microglial phagocytosis of amyloid-β 1-42 (Aβ42); however, the mechanisms underlying the protective mechanism remain further investigation. We aim to investigate the effects of MaR1 on microglial chemotaxis and activation in this study. Both indirect and direct primary neuron and microglia co-culture system was used in this study. Our results showed MaR1 downregulated the increased microglial chemotaxis induced by Aβ42. The microglial inactivation marker CD200R was downregulated by Aβ42 and upregulated by MaR1. Pro-inflammatory cytokines secretion such as tumor necrosis factor (TNF)-α were increased by Aβ42 and these changes were revised by MaR1 treatment. In addition, the levels of chemokine monocyte chemoattractant protein (MCP)-1 were increased while the levels of anti-inflammatory factor IL-10 secretion were decreased by Aβ42, and these changes were abolished by MaR1 treatment. Moreover, by proteomics analysis, we identified cell signaling pathways affected by MaR1 were not only limited to inflammation-related pathways such as P38, but also in pathways involved in cell survival, autophagy, axon formation, and apoptosis, including PI3K/AKT, mTOR, ERK, caspase3, Cdc42, and p75NTR. In conclusion, MaR1 promoted inflammation resolution by inhibiting chemotaxis and regulating activation of microglia. MaR1 played a neuroprotective role by affecting cell signaling pathways involving inflammation, cell survival, autophagy, axon formation, and apoptosis inhibition.
CagninA, BrooksDJ, KennedyAM, GunnRN, MyersR, TurkheimerFE, JonesT, BanatiRB (2001) In-vivo measurement of activated microglia in dementia. Lancet358, 461–467.
3.
GriffinWS, StanleyLC, LingC, WhiteL, MacLeodV, PerrotLJ, WhiteCL3rd,AraozC (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A86, 7611–7615.
4.
SwardfagerW, LanctotK, RothenburgL, WongA, CappellJ, HerrmannN (2010) A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry68, 930–941.
5.
WangX, ZhuM, HjorthE, Cortes-ToroV, EyjolfsdottirH, GraffC, NennesmoI, PalmbladJ, EriksdotterM, SambamurtiK, FitzgeraldJM, SerhanCN, GranholmAC, SchultzbergM (2015) Resolution of inflammation is altered in Alzheimer’s disease. Alzheimers Dement11, 40–50e42.
6.
SerhanCN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature510, 92–101.
7.
ArnardottirH, OrrSK, DalliJ, SerhanCN (2016) Human milk proresolving mediators stimulate resolution of acute inflammation. Mucosal Immunol9, 757–766.
8.
ChiangN, SerhanCN (2017) Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Mol Aspects Med58, 114–129.
9.
DalliJ, SerhanCN (2017) Pro-resolving mediators in regulating and conferring macrophage function. Front Immunol8, 1400.
10.
SerhanCN (2017) Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms. FASEB J31, 1273–1288.
11.
LukiwWJ, CuiJG, MarcheselliVL, BodkerM, BotkjaerA, GotlingerK, SerhanCN, BazanNG (2005) A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest115, 2774–2783.
MedeirosR, KitazawaM, PassosGF, Baglietto-VargasD, ChengD, CribbsDH, LaFerlaFM (2013) Aspirin-triggered lipoxin A4 stimulates alternative activation of microglia and reduces Alzheimer disease-like pathology in mice. Am J Pathol182, 1780–1789.
15.
DunnHC, AgerRR, Baglietto-VargasD, ChengD, KitazawaM, CribbsDH, MedeirosR (2015) Restoration of lipoxin A4 signaling reduces Alzheimer’s disease-like pathology in the 3xTg-AD mouse model. J Alzheimers Dis43, 893–903.
16.
KantarciA, AytanN, PalaskaI, StephensD, CrabtreeL, BenincasaC, JenkinsBG, CarrerasI, DedeogluA (2018) Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer’s disease. Exp Neurol300, 111–120.
17.
SauraJ, TusellJM, SerratosaJ (2003) High-yield isolation of murine microglia by mild trypsinization. Glia44, 183–189.
18.
NodaM, SuzumuraA (2012) Sweepers in the CNS: Microglial migration and phagocytosis in the Alzheimer disease pathogenesis. Int J Alzheimers Dis2012, 891087.
19.
CondelloC, YuanP, SchainA, GrutzendlerJ (2015) Microglia constitute a barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. Nat Commun6, 6176.
HickmanSE, AllisonEK, El KhouryJ (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci28, 8354–8360.
22.
Koenigsknecht-TalbooJ, LandrethGE (2005) Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci25, 8240–8249.
23.
YangT, XuG, NewtonPT, ChaginAS, MkrtchianS, CarlstromM, ZhangXM, HarrisRA, CooterM, BergerM, MaddipatiKR, AkassoglouK, TerrandoN (2019) Maresin 1 attenuates neuroinflammation in a mouse model of perioperative neurocognitive disorders. Br J Anaesth122, 350–360.
24.
CombsCK, KarloJC, KaoSC, LandrethGE (2001) beta-Amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci21, 1179–1188.
25.
MurphyGMJr, YangL, CordellB (1998) Macrophage colony-stimulating factor augments beta-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells. J Biol Chem273, 20967–20971.
26.
WoodLB, WinslowAR, ProctorEA, McGuoneD, MordesDA, FroschMP, HymanBT, LauffenburgerDA, HaigisKM (2015) Identification of neurotoxic cytokines by profiling Alzheimer’s disease tissues and neuron culture viability screening. Sci Rep5, 16622.
27.
SteelandS, GorleN, VandendriesscheC, BalusuS, BrkicM, Van CauwenbergheC, Van ImschootG, Van WonterghemE, De RyckeR, KremerA, LippensS, StopaE, JohansonCE, LibertC, VandenbrouckeRE (2018) Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer’s disease. EMBO Mol Med10, e8300.
28.
RingheimGE, SzczepanikAM, PetkoW, BurgherKL, ZhuSZ, ChaoCC (1998) Enhancement of beta-amyloid precursor protein transcription and expression by the soluble interleukin-6 receptor/interleukin-6 complex. Brain Res Mol Brain Res55, 35–44.
29.
ZilkaN, KazmerovaZ, JadhavS, NeradilP, MadariA, ObetkovaD, BugosO, NovakM (2012) Who fans the flames of Alzheimer’s disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways. J Neuroinflammation9, 47.
30.
GaoJ, TangC, TaiLW, OuyangY, LiN, HuZ, ChenX (2018) Pro-resolving mediator maresin 1 ameliorates pain hypersensitivity in a rat spinal nerve ligation model of neuropathic pain. J Pain Res11, 1511–1519.
31.
El KhouryJ (2010) Neurodegeneration and the neuroimmune system. Nat Med16, 1369–1370.
32.
KoningN, SwaabDF, HoekRM, HuitingaI (2009) Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol68, 159–167.
33.
MatsumotoH, KumonY, WatanabeH, OhnishiT, TakahashiH, ImaiY, TanakaJ (2007) Expression of CD200 by macrophage-like cells in ischemic core of rat brain after transient middle cerebral artery occlusion. Neurosci Lett418, 44–48.
34.
ZhangS, WangXJ, TianLP, PanJ, LuGQ, ZhangYJ, DingJQ, ChenSD (2011) CD200-CD200R dysfunction exacerbates microglial activation and dopaminergic neurodegeneration in a rat model of Parkinson’s disease. J Neuroinflammation8, 154.
35.
WalkerDG, Dalsing-HernandezJE, CampbellNA, LueLF (2009) Decreased expression of CD200 and CD200 receptor in Alzheimer’s disease: A potential mechanism leading to chronic inflammation. Exp Neurol215, 5–19.
HanYH, ShinKO, KimJY, KhadkaDB, KimHJ, LeeYM, ChoWJ, ChaJY, LeeBJ, LeeMO (2019) A maresin 1/RORalpha/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis. J Clin Invest130, 1684–1698.
38.
RecabarrenD, AlarconM (2017) Gene networks in neurodegenerative disorders. Life Sci183, 83–97.
39.
KriplaniN, HermidaMA, BrownER, LeslieNR (2015) Class I PI 3-kinases: Function and evolution. Adv Biol Regul59, 53–64.
40.
WangY, WuC, HanB, XuF, MaoM, GuoX, WangJ (2016) Dexmedetomidine attenuates repeated propofol exposure-induced hippocampal apoptosis, PI3K/Akt/Gsk-3beta signaling disruption, and juvenile cognitive deficits in neonatal rats. Mol Med Rep14, 769–775.
41.
KimKC, LeeIK, KangKA, ChaJW, ChoSJ, NaSY, ChaeS, KimHS, KimS, HyunJW (2013) 7,8-Dihydroxyflavone suppresses oxidative stress-induced base modification in DNA via induction of the repair enzyme 8-oxoguanine DNA glycosylase-1. Biomed Res Int2013, 863720.
42.
ChamiB, SteelAJ, De La MonteSM, SutherlandGT (2016) The rise and fall of insulin signaling in Alzheimer’s disease. Metab Brain Dis31, 497–515.
43.
D’AntoniS, RannoE, SpatuzzaM, CavallaroS, CataniaMV (2017) Endothelin-1 induces degeneration of cultured motor neurons through a mechanism mediated by nitric oxide and PI3K/Akt pathway. Neurotox Res32, 58–70.
44.
ColaiannaM, TucciP, ZottiM, MorgeseMG, SchiavoneS, GovoniS, CuomoV, TrabaceL (2010) Soluble beta amyloid(1-42): A critical player in producing behavioural and biochemical changes evoking depressive-related state?Br J Pharmacol159, 1704–1715.
45.
PassosGF, FigueiredoCP, PredigerRD, SilvaKA, SiqueiraJM, DuarteFS, LealPC, MedeirosR, CalixtoJB (2010) Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Brain Behav Immun24, 493–501.
46.
O’NeillC (2013) PI3-kinase/Akt/mTOR signaling: Impaired on/off switches in aging, cognitive decline and Alzheimer’s disease. Exp Gerontol48, 647–653.
47.
PerluigiM, PupoG, TramutolaA, CiniC, CocciaR, BaroneE, HeadE, ButterfieldDA, Di DomenicoF (2014) Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. Biochim Biophys Acta1842, 1144–1153.
48.
TramutolaA, LanzillottaC, Di DomenicoF (2017) Targeting mTOR to reduce Alzheimer-related cognitive decline: From current hits to future therapies. Expert Rev Neurother17, 33–45.
49.
TramutolaA, LanzillottaC, BaroneE, ArenaA, ZulianiI, MoscaL, BlarzinoC, ButterfieldDA, PerluigiM, Di DomenicoF (2018) Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Transl Neurodegener7, 28.
50.
KimS, JingK, ShinS, JeongS, HanSH, OhH, YooYS, HanJ, JeonYJ, HeoJY, KweonGR, ParkSK, ParkJI, WuT, LimK (2018) omega3-polyunsaturated fatty acids induce cell death through apoptosis and autophagy in glioblastoma cells: In vitro and in vivo. Oncol Rep39, 239–246.
51.
LismanJ (2003) Long-term potentiation: Outstanding questions and attempted synthesis. Philos Trans R Soc Lond B Biol Sci358, 829–842.
52.
SmolenP, BaxterDA, ByrneJH (2006) A model of the roles of essential kinases in the induction and expression of late long-term potentiation. Biophys J90, 2760–2775.
53.
GieseKP, MizunoK (2013) The roles of protein kinases in learning and memory. Learn Mem20, 540–552.
54.
LiH, KangT, QiB, KongL, JiaoY, CaoY, ZhangJ, YangJ (2016) Neuroprotective effects of ginseng protein on PI3K/Akt signaling pathway in the hippocampus of D-galactose/AlCl3 inducing rats model of Alzheimer’s disease. J Ethnopharmacol179, 162–169.
55.
PengS, ZhangY, ZhangJ, WangH, RenB (2010) ERK in learning and memory: A review of recent research. Int J Mol Sci11, 222–232.
56.
ChongYH, ShinYJ, LeeEO, KayedR, GlabeCG, TennerAJ (2006) ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem281, 20315–20325.
57.
AroraK, ChengJ, NicholsRA (2015) Nicotinic acetylcholine receptors sensitize a MAPK-linked toxicity pathway on prolonged exposure to beta-amyloid. J Biol Chem290, 21409–21420.
58.
SunA, LiuM, NguyenXV, BingG (2003) P38 MAP kinase is activated at early stages in Alzheimer’s disease brain. Exp Neurol183, 394–405.
59.
HensleyK, FloydRA, ZhengNY, NaelR, RobinsonKA, NguyenX, PyeQN, StewartCA, GeddesJ, MarkesberyWR, PatelE, JohnsonGV, BingG (1999) p38 kinase is activated in the Alzheimer’s disease brain. J Neurochem72, 2053–2058.
60.
SchnoderL, HaoW, QinY, LiuS, TomicI, LiuX, FassbenderK, LiuY (2016) Deficiency of neuronal p38alpha MAPK attenuates amyloid pathology in Alzheimer disease mouse and cell models through facilitating lysosomal degradation of BACE1. J Biol Chem291, 2067–2079.
61.
MarberMS, RoseB, WangY (2011) The p38 mitogen-activated protein kinase pathway–a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol51, 485–490.
62.
CohenSB, ChengTT, ChindaloreV, DamjanovN, Burgos-VargasR, DeloraP, ZimanyK, TraversH, CaulfieldJP (2009) Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum60, 335–344.
63.
LinX, WangM, ZhangJ, XuR (2014) p38 MAPK: A potential target of chronic pain. Curr Med Chem21, 4405–4418.
64.
ArthurJS, LeySC (2013) Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol13, 679–692.
65.
LeeJK, KimNJ (2017) Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of Alzheimer’s disease. Molecules22, E1287.
66.
ShimohamaS, TaninoH, FujimotoS (1999) Changes in caspase expression in Alzheimer’s disease: Comparison with development and aging. Biochem Biophys Res Commun256, 381–384.
67.
SnigdhaS, SmithED, PrietoGA, CotmanCW (2012) Caspase-3 activation as a bifurcation point between plasticity and cell death. Neurosci Bull28, 14–24.
68.
ChakravarthyB, GaudetC, MenardM, AtkinsonT, BrownL, LaferlaFM, ArmatoU, WhitfieldJ (2010) Amyloid-beta peptides stimulate the expression of the p75(NTR) neurotrophin receptor in SHSY5Y human neuroblastoma cells and AD transgenic mice. J Alzheimers Dis19, 915–925.
69.
WangYJ, WangX, LuJJ, LiQX, GaoCY, LiuXH, SunY, YangM, LimY, EvinG, ZhongJH, MastersC, ZhouXF (2011) p75NTR regulates Abeta deposition by increasing Abeta production but inhibiting Abeta aggregation with its extracellular domain. J Neurosci31, 2292–2304.
70.
YaarM, ZhaiS, PanovaI, FineRE, EisenhauerPB, BlusztajnJK, Lopez-CoviellaI, GilchrestBA (2007) A cyclic peptide that binds p75(NTR) protects neurones from beta amyloid (1-40)-induced cell death. Neuropathol Appl Neurobiol33, 533–543.
XuG, NieDY, ChenJT, WangCY, YuFG, SunL, LuoXG, AhmedS, DavidS, XiaoZC (2004) Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: A potential strategy for axonal regeneration. J Neurochem91, 1018–1023.
73.
NieDY, XuG, AhmedS, XiaoZC (2007) DNA vaccine and the CNS axonal regeneration. Curr Pharm Des13, 2500–2506.
74.
SchwambornJC, PuschelAW (2004) The sequential activity of the GTPases Rap1B and Cdc42 determines neuronal polarity. Nat Neurosci7, 923–929.
75.
ZhuX, RainaAK, BouxH, SimmonsZL, TakedaA, SmithMA (2000) Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. Int J Dev Neurosci18, 433–437.
76.
Mendoza-NaranjoA, Gonzalez-BillaultC, MaccioniRB (2007) Abeta1-42 stimulates actin polymerization in hippocampal neurons through Rac1 and Cdc42 Rho GTPases. J Cell Sci120, 279–288.
77.
SaracenoC, CataniaM, PaterliniA, FostinelliS, CianiM, ZanardiniR, BinettiG, Di FedeG, CaroppoP, BenussiL, GhidoniR, BologninS (2018) Altered expression of circulating Cdc42 in frontotemporal lobar degeneration. J Alzheimers Dis61, 1477–1483.
